Imagine Pharma, a Pittsburgh, PA-based biotech company focused on the commercialization opportunities related to its novel IMG-1 polypeptide, raised $32.5M in Series A funding.
The round, with an initial traunch of $10M, which brought the total funding to date to $40M, was led by IP Investors. John T. Callaghan, CPA CFE, representing the investor group, will join the board.
The company intends to use the funds to advance its priority programs in regenerative medicine, oral delivery, and therapeutics. Specific programs to be funded through this investment include:
- Commercialization of a novel nutritional supplement
- Completion of pre-clinical studies and IND submittal for oral erythropoietin and glucagon-like peptide-1 (GLP-1) receptor agonists
- Advancement of AIPC research collaboration with LyGenesis
- Further expansion of the company’s islet isolation services business
- Strategic partnership development across all platforms
Led by co-CEOs Dr. Ngoc Thai (Founder) and Santiago Pujadas, Imagine Pharma is a biotechnology company focused on the development of its IMG-1 polypeptide. Research and development efforts have led to the development of three distinctive platforms for Oral Delivery, Therapeutics, and Regenerative Medicine, each with programs that address multiple disease states in large, underserved markets. Founded in 2016, Imagine Pharma is an approved Islet Isolation Center for the National Institute of Diabetes and Digestive and Kidney Diseases Integrated Islet Distribution Program.
FinSMEs
31/10/2023